Here’s what you should know:
1. Takeda closed its first bid, agreeing to buy TiGenix’s shares on a fully diluted basis.
2. Takeda is launching a second acceptance period in an attempt to acquire the remaining securities June 6. The bid will expire July 3.
3. Takeda announced the acquisition in January.
4. Takeda Gastroenterology Therapeutic Area Unit Head Asit Parikh said, “Takeda and TiGenix share a common mission of advancing innovative therapies to improve the lives of patients with gastrointestinal disorders, and we are pleased to welcome TiGenix to Takeda with the close of this deal. This is an exciting step forward as we expand our global, late-stage GI pipeline and strengthen our presence in the U.S. specialty care market.”
More articles on gastroenterology:
How an Oregon-based ASC combats decreasing case volume
All hands on deck: Pinnacle III VP’s 10 strategies for building ASC teamwork
ASGE raising awareness of esophageal adenocarcinoma — 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
